Upload
pacific-bridge-medical
View
1.042
Download
6
Embed Size (px)
DESCRIPTION
This whitepaper provides an overview of Chinese pharmaceutical market access. This includes an overview of the Chinese pharmaceutical market, government regulatory bodies,distribution channels, demographics, pricing and insurance. It also includes an overview of current regulations and product registration procedures. This paper is meant for anyone within the pharmaceutical industry who is looking to learn more about how to access the pharmaceutical market in China. For more information, contact us for a free 15 minute consultation at http://www.pacificbridgemedical.com/contact-us/.
Citation preview
Pacific Bridge Medical2013 White Paper
China: Pharmaceutical Market Access
www.pacificbridgemedical.com
Pacific Bridge Medical2013 White Paper
China: Pharmaceutical Regulations
Copyright © 2013 Pacific Bridge Medical. All rights reserved. This content is protected by US and International copyright laws and may not be copied, reprinted, published, trans-lated, resold, hosted, or otherwise distributed by any means without explicit permission. Disclaimer: the information contained in this report is the opinion of Pacific Bridge Medi-cal, a subsidiary of Pacific Bridge, Inc. It is provided for general information purposes only, and does not constitute professional advice. We believe the contents to be true and accurate at the date of writing but can give no assurances or warranties regarding the ac-curacy, currency, or applicability of any of the contents in relation to specific situations and particular circumstances.
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 3
Map of China
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 4
China has become the 3rd largest pharma market globally since 2011
China Pharmaceutical Market Size
USD Bn (@ex-factory value)
CAGR:21%
(‘03-’11)
CAGR:19-22%(‘11-’15)
Source: IMS Health, MENET China
Top 4 Pharmaceutical Markets, 2011 (Estimated)
1. US $310 billion
2. Japan $102 billion
3. China $41 billion
4. Germany $40 billion
Note: IMS data tends to under-estimate China’s market
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 5
The pharma market is still relatively concentrated in coastal areas,especially for MNCs
Sales Distribution by Area
Top 10 SalesGuangdong 11.6%Zhejiang 7.1%Jiangsu 6.8%Shandong 6.4%Liaoning 5.8%Shanghai 5.3%Beijing 4.5%Hubei 4.2%Hebei 4.2%Henan 4.0%
Source: China Association of Pharmaceutical Commerce. ChinaGovernment Statistics, Data Analysis
Entire Market~52%
MNCs>70%
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 6
Multiple government agencies areresponsible for policy-making and for monitoring the industry
* This org structure is replicated at provincial level
State agencies governing the pharmaceutical industry in China*
RegulatoryDivision
Ministryof Health MoHRSS NDRC
Planning andFinancial Division
Drug Policy andEssential DrugPolicy Division
SFDA
RegulatoryDivision
DrugRegistration
Division
MedicalInsuranceDivision
PricingDivision
PharmaceuticalsPricing
Division
• MoHRSS: Ministry of Human Resources and Social Securities
• NDRC: National Development and Reform Commission
• SFDA: State Food and Drug Ad-ministration
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 7
Hospitals are the main channel of drug dispension.The OTC market is growing faster. TCMs take about 36% market share
Source: SFDA Statistics, MOH Statistics, Data Analysis
Sales Distribution by Channel Sales Distribution by Drug Type -- OTC Market
Sales Distribution by Drug Type -- Hospital Market
11%
26% 63%
12%
49%39%
17%
35%
47%
* Others: small street clinics, etc *** Others: health foods/tonics/ bio-tech drugs, etc
** Others: bio-tech drugs, etc
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 8
Key Characteristics of ChinaPharmaceutical Market
China pharma market is growing fast, but it is still a self-pay market
Generics dominate market by volume with lower price, market share of value keeps growing
One product with dozens of manufacturers (for example: 29 Erythropoietin producers)
Typical China Rx “blockbuster” is about USD 100 million in annual sales
The pharma market is still relatively concentrated in coastal areas, especially for MNCs
Hospitals are the main channel of drug dispensing. The hospital market will be shifting to medium and small cities
Rx market represents about 75% market share. The OTC market is growing faster.
❖
♦
❖
❖
❖
❖
❖
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 9
Key Characteristics of ChinaPharmaceutical Market (cont.)
WMs (Western Medicines) represent about 64% market share and TCMs (Traditional Chinese Medicines) take about 36% market share
The level of spending per patient is significantly higher in large hospitals
Low pricing and kickbacks to doctors are the major marketing strategies for most of local companies
Government policy of pricing restrictions. Price cut has significant impact on drug sales
Health insurance reform keeps on going
Drug expenditure per capita in urban areas is much higher than that in rural areas
❖
❖
❖
❖
❖
❖
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 10
Key Characteristics of ChinaPharmaceutical Market (cont.)
Urban and rural areas exhibit slight difference in disease patterns
Higher infectious disease rates in rural areas
With the industry modernization, pollution becoming a serious problem in some areas; Respiratory diseases have high prevalence (even growing in some regions)
Higher cancer and cardiovascular disease rates in urban areas
With income increasing, the price sensitivity is going down; people are more brand selective
❖
❖
♦
♦
♦
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 11
Navigating the market in China is no easy task, as the value chain involves a complex set of stakeholders
Illustration of the business of Rx commercialization in China
Approval of New Drug
(RDL* &)Approval of Drug Price
Tendering& Bidding
HospitalListing
PhysicianPrescribing Dispensing
Key constituents -• Drug manufacturers• Distributors• Central government: various agencies• Provincial governments: various agencies• Hospitals: various classes and levels• KOLs and physicians
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 12
A series of provisions and guidelines regulate drug development andapproval in China
Scope of Regulations• Approval for conducting clinical trials (IND)• Approval for new drug manufacturing• Approval for marketing license (NDA)• Registration supplements• Renewal of license
Type of Drugs• New drugs• Generic drugs• Imported drugs
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 13
A series of provisions and guidelines regulate drug development andapproval in China
• Also sub-classes within each broad class• Since 2010, Class 6 has been separated out and subject to independent review and approval process under Generic Drugs
TraditionalChinese
Medicines andBotanical Drugs
• 11 classes
Chemical Drugs
1. Molecule has not beenapproved anywhere globally
2. New route of delivery which has not beenapproved anywhere globally
3. Molecule has been ap-proved overseas but not in China yet
4. New salts of an approved molecule
5. New dosage forms of an approved molecule
6. Generics
Biologics
• 15 Classes
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 14
Drug Applications
Generic Drug Applications
Generic applications can be used for drugs that already have National Standards in China or are listed in the Chinese Pharmacopoeia
Class 6 of chemical drugs, Class 15 of preventative biological products, Class 15 of therapeutic biological drugs, and Class 9 of traditional Chinese medicine and natural drugs fall into this category
Imported Drug Applications
All drugs manufactured outside China must be registered via the imported drug application, even if they are new drugs.
❖
♦
♦
❖
♦
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 15
Registration Supplements
For changes to already-approved drugs
Total of 33 kinds of supplements
17 of these require the SFDA’s approval
10 situations require approval from the provincial drug authority (PDA), or alternatively can just be filed for record (without approval) with the SFDA
Final 6 situations can be filed for record with the PDA
❖
♦
❖
♦
♦
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 16
Application documents for Newdrug registration
The SFDA has issued a detailed documentation list for chemical drugs, biological products, and traditional Chinese medicine
The SFDA has issued technical guidance for some document sections
Adopted CTD format for submission since 2010
If the products are imported, the SFDA will also accept drugs prepared in accordance with ICH guidelines
❖
♦
❖
♦
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 17
Data requirements are itemizedaccording to drug classificationdesignated by SFDA
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 18
For an imported new drug, it takesapprox 36– 42 months from INDsubmission to NDA approval
Step 1:
Application forconducting clinical trials (INDApplication)
Step 2:
Conducting clinical trials
Step 3:
Application for imported drug registration(NDA Review & Approval)
Takes 7 - 10 months
Timeline pending upon the scale of clinical development, which in turn depends on the New Drug Classification
Takes 7 - 15 months
(SFDA, NSCPBP)
(Applicant)
(SFDA; NSCPBP)
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 19
Drug development in China –IND approvals
IND Approvals in China
2006 2007 2008 2009 2010New molecules/formulations (local)
N/A N/A N/A 288 141
Generics (local) N/A N/A N/A 196 153
Imported Drugs N/A N/A N/A 320 308
Total 1,426 758 581 804 602
Anti-corruption reforms in 2006-2007 began to set moreglobalized standard
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 20
It takes up to 15 months for a brandto be prescribed after receivingSFDA’s approval
Approval of Drug Price Provincial Bidding Hospital Listing
4 - 5 months
• A drug must obtain its ap-proved retail price before entering the bidding process
• If the drug is on the NRDL, its price is set by NDRC• If the drug is not on NDRL, the manufacturer must get its retail price approved by provincial government s (The Pricing Bureau)
• Approx. 3 months to get price approval at the prov-ince where the company is registered
• Additional 1-2 months to get price at other provinces
• The process needs to be carried out at each prov-ince individually
3 - 5 months
• Each Province will select a few (2-5 suppliers) for each drug (molecule, dos-age form, dose strength) – the bidding process
• The bidding schedules (a few times a year) are set by provincial governments
• Whether or not the drug is or not on RDL, bidding process is a MUST before entering hospitals
• Manufacturers need to go through the bidding process province by province
• Each bidding process takes approx. 3 months
3 - 5 months
• Once a product wins bid-ding at a province, it will then need to obtain listing by hospitals
• Hospital Listing is the contract that a hospital has agreed to carry the product
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 21
NDRC implemented 2 price-cuts in 2011, which was very unusual
1st price-cut in 2011
• In late March
• 162 molecules and close to 1,300 dosage form specs
• Infectious, cardiovascular and circulatory diseases, antibiotics
• Approx. 20% cut on retail price
2nd price-cut in 2011
• In September
• 80 molecules
• Hormones, endocrine and nervous system disorders
• Approx. 14% cut on retail price
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 22
Drug pricing in China is based on a combination of free-market andstate- control mechanisms
Essential Drug List – EDL• Issued by MOH• Mainly old generic drugs• 100% reimbursed by the government• Retail price set by NDRC
List A drugs – NRDL• Issued by MoHRSS• Mainly old generic drugs, over-laps with EDL• 100% reimbursed by the government• Retail price set by NDRC
List B* drugs – NRDL and PRDL • MOHRSS proposes National RDL List B, consisting of innovative and premium-priced drugs• Provinces may substitute 15% of List B to address local need• Retail price set by NDRC and Provincial Pricing Bureau (PB)• Patient’s co-pay ranges 10%-90%
Copyright © 2013 Pacific Bridge Medical | www.pacificbridgemedical.com 23
Thank You!
Pacific Bridge MedicalConnect with us today.
7315 Wisconsin Avenue, Suite 609E Bethesda, MD 20814
www.pacificbridgemedical.com
Click here to contact us about assisting your company’s access to the China pharmaceutical market.